Assertio Therapeutics (ASRT) Stock Statistics & Valuation Metrics

Assertio Therapeutics has a market cap or net worth of $65.52M. The enterprise value is $1.27B.

Assertio Therapeutics has 6,416,806 shares outstanding. The number of shares has decreased by -2.65% in one year.

Assertio Therapeutics’s return on equity (ROE) is -0.18 and return on invested capital (ROIC) is -14.40%.

The current PE Ratio of Assertio Therapeutics is ―. Assertio Therapeutics’s PEG ratio is 0.61.

In the last 12 months, Assertio Therapeutics had revenue of 124.96M and earned -21.58M in profits. Earnings per share was -3.45.

In the last 12 months, operating cash flow was 13.33M and capital expenditures 0.00, giving a free cash flow of 13.33M billion.

Assertio Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Assertio Therapeutics upcoming earnings date is Mar 11, 2026, Before Open (Confirmed).

Assertio Therapeutics as a current ratio of 1.77, with Debt / Equity ratio of 37.02%

In the past 12 months, Assertio Therapeutics has paid 52.00K in taxes.

Assertio Therapeutics EV to EBITDA ratio is 239.97, with an EV/FCF ratio of 46.76.

Assertio Therapeutics has $93.43M in cash and marketable securities with $39.17M in debt, giving a net cash position of $54.26M billion.

Gross margin is 68.16%, with operating margin of -19.59%, and net profit margin of -17.27%.

The average price target for Assertio Therapeutics is $27.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy